BR9709105A - Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv - Google Patents

Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv

Info

Publication number
BR9709105A
BR9709105A BR9709105A BR9709105A BR9709105A BR 9709105 A BR9709105 A BR 9709105A BR 9709105 A BR9709105 A BR 9709105A BR 9709105 A BR9709105 A BR 9709105A BR 9709105 A BR9709105 A BR 9709105A
Authority
BR
Brazil
Prior art keywords
inhibitors
pde
tnf
quinoline sulfonamides
sulfonamides
Prior art date
Application number
BR9709105A
Other languages
English (en)
Inventor
Hazel Joan Dyke
John Gary Montana
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9610506.9A external-priority patent/GB9610506D0/en
Priority claimed from GBGB9623234.3A external-priority patent/GB9623234D0/en
Priority claimed from GBGB9626883.4A external-priority patent/GB9626883D0/en
Priority claimed from GBGB9708071.7A external-priority patent/GB9708071D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of BR9709105A publication Critical patent/BR9709105A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9709105A 1996-05-20 1997-05-20 Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv BR9709105A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9610506.9A GB9610506D0 (en) 1996-05-20 1996-05-20 Novel compounds
GBGB9623234.3A GB9623234D0 (en) 1996-11-07 1996-11-07 Novel compounds
GBGB9626883.4A GB9626883D0 (en) 1996-12-24 1996-12-24 Compounds
GBGB9708071.7A GB9708071D0 (en) 1997-04-22 1997-04-22 Compounds
PCT/GB1997/001360 WO1997044322A1 (en) 1996-05-20 1997-05-20 Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors

Publications (1)

Publication Number Publication Date
BR9709105A true BR9709105A (pt) 1999-08-03

Family

ID=27451450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709105A BR9709105A (pt) 1996-05-20 1997-05-20 Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv

Country Status (8)

Country Link
US (1) US5834485A (pt)
EP (1) EP0912519A1 (pt)
JP (1) JP2000510866A (pt)
CN (1) CN1219168A (pt)
AU (1) AU722662B2 (pt)
BR (1) BR9709105A (pt)
CA (1) CA2252501A1 (pt)
WO (1) WO1997044322A1 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) * 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
ES2195419T3 (es) * 1997-11-25 2003-12-01 Warner Lambert Co Inhibidores bencenosulfonamida de pde-iv y su uso terapeutico.
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EA006685B1 (ru) 1999-08-21 2006-02-24 Алтана Фарма Аг Синергетическая композиция
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
IL162506A0 (en) 2001-12-14 2005-11-20 Applied Research Systems Ovulation induction
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
TWI328009B (en) * 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
EP1740208A2 (en) * 2004-03-23 2007-01-10 Amgen, Inc Monoclonal antibodies specific for human ox40l (cd134l)
US7511062B2 (en) * 2004-05-18 2009-03-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
DK1773816T3 (en) 2004-06-24 2015-01-26 Vertex Pharma Modulators of ATP-binding cassette transporters
GB0503955D0 (en) * 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
DE102005045060B4 (de) * 2005-09-21 2007-07-05 Infineon Technologies Ag Integrierte Schaltungsanordnung mit mehreren Leitstrukturlagen und Verfahren zu ihrer Herstellung
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7919505B2 (en) * 2006-07-11 2011-04-05 Schering Corporation Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101679357A (zh) * 2007-05-09 2010-03-24 辉瑞大药厂 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途
KR101709141B1 (ko) 2008-01-25 2017-02-22 브이티브이 테라퓨틱스 엘엘씨 TNF-α 합성의 조절자 및 PDE4 억제제로서 3고리 화합물
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
PL2448582T3 (pl) 2009-06-29 2017-09-29 Agios Pharmaceuticals, Inc. Pochodne chinolino-8-sulfonamidowe mające działanie przeciwnowotworowe
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
EP2491145B1 (en) 2009-10-21 2016-03-09 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP5837091B2 (ja) 2010-12-17 2015-12-24 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼm2(pkm2)調節剤としての新規n−(4−(アゼチジン−1−カルボニル)フェニル)−(ヘテロ−)アリールスルホンアミド誘導体
US9328077B2 (en) 2010-12-21 2016-05-03 Agios Pharmaceuticals, Inc Bicyclic PKM2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN103764147B (zh) 2011-05-03 2018-05-22 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
ES2746558T3 (es) 2011-05-03 2020-03-06 Agios Pharmaceuticals Inc Activadores de piruvato cinasa R para uso en terapia
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN108912066B (zh) 2012-01-06 2022-06-24 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
AU2013331626B2 (en) 2012-10-15 2018-08-02 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3250209B1 (en) 2015-01-30 2023-09-13 Lieber Institute For Brain Development Comt inhibiting methods and compositions
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase
AU2016338552B2 (en) 2015-10-15 2022-04-28 Les Laboratoires Servier Combination therapy for treating malignancies
EA039829B1 (ru) 2015-10-15 2022-03-17 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей
EP3380471B8 (en) 2015-11-25 2022-01-19 Lieber Institute Inc. DBA Lieber Institute For Brain Development Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61169845A (ja) * 1985-01-23 1986-07-31 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH02184673A (ja) * 1989-01-11 1990-07-19 Yoshitomi Pharmaceut Ind Ltd スルホンアミド化合物
US5340811A (en) * 1990-03-08 1994-08-23 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinoline-or quinoline-sulfonamide derivative and a pharmaceutical composition comprising the same
JPH03258763A (ja) * 1990-03-09 1991-11-19 Asahi Chem Ind Co Ltd スルホンアミド誘導体及びそれを含有する医薬組成物
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
US5646677A (en) * 1995-02-23 1997-07-08 Motorola, Inc. Method and apparatus for interactively viewing wide-angle images from terrestrial, space, and underwater viewpoints
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Also Published As

Publication number Publication date
AU722662B2 (en) 2000-08-10
JP2000510866A (ja) 2000-08-22
EP0912519A1 (en) 1999-05-06
CN1219168A (zh) 1999-06-09
CA2252501A1 (en) 1997-11-27
US5834485A (en) 1998-11-10
AU2905997A (en) 1997-12-09
WO1997044322A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
BR9709105A (pt) Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
PT946512E (pt) Derivados de 6-fenilpiridil-2-amina uteis como inibidores de nos
PT936912E (pt) Inibidores de cisteina protease
LV12150A (lv) Farneziltransferazes inhibitori
MA26771A1 (fr) Benzoheterocycles et leur utilisation comme inhibiteurs de mek.
DE59611425D1 (de) Messfühler
NO975894L (no) Foringsr°rpakning
DE69716615T2 (de) Heterozyklische metalloproteaseinhibitoren
DE69705112T2 (de) Coralynanaloge als topoisomerase inhibitoren
PT958287E (pt) Inibidores de sulfamida-metaloprotease
DE69708751D1 (de) Messfühler
DE69710479D1 (de) Organomineralgel zur dekontamination von oberflächen
PT927183E (pt) Inibidores espirociclicos de metaloproteases
ATE268781T1 (de) Thrombininhibitoren
NO992104D0 (no) Isokinoloner
ATE236884T1 (de) Pde-iv hemmende 2-cyanoiminoimidazol-derivate
BR9708655A (pt) Derivados de isatina como inibidores de acetilcolinesterase e analgésicos
PT1023268E (pt) Isoquinolinas como inibidores de uroquinase
IS4898A (is) Sáraumbúðir
DE69709833D1 (de) Wellenformentzerrer
BR9701283A (pt) Conexão de encaixe descartável
PT1214302E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao como inibidores de lipase
DE69730551D1 (de) Hydroxyperoxide Lyasen
DE69723404D1 (de) Elektrode
DE69731664D1 (de) Thrombininhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.